Charles River Laboratories Total Assets 2006-2018 | CRL

Charles River Laboratories total assets from 2006 to 2018. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Charles River Laboratories total assets for the quarter ending December 31, 2018 were $3.856B, a 31.6% increase year-over-year.
  • Charles River Laboratories total assets for 2018 were $3.856B, a 31.6% increase from 2017.
  • Charles River Laboratories total assets for 2017 were $2.93B, a 8.04% increase from 2016.
  • Charles River Laboratories total assets for 2016 were $2.712B, a 31.1% increase from 2015.
Charles River Laboratories Annual Total Assets
(Millions of US $)
2018 $3,856
2017 $2,930
2016 $2,712
2015 $2,068
2014 $1,871
2013 $1,633
2012 $1,586
2011 $1,558
2010 $1,733
2009 $2,204
2008 $2,141
2007 $2,806
2006 $2,558
2005 $2,538
Charles River Laboratories Quarterly Total Assets
(Millions of US $)
Q4 2018 $3,856
Q3 2018 $3,797
Q2 2018 $3,866
Q1 2018 $3,001
Q4 2017 $2,930
Q3 2017 $2,866
Q2 2017 $2,774
Q1 2017 $2,697
Q4 2016 $2,712
Q3 2016 $2,690
Q2 2016 $2,763
Q1 2016 $2,104
Q4 2015 $2,068
Q3 2015 $2,033
Q2 2015 $1,886
Q1 2015 $1,847
Q4 2014 $1,871
Q3 2014 $1,842
Q2 2014 $1,863
Q1 2014 $1,652
Q4 2013 $1,633
Q3 2013 $1,644
Q2 2013 $1,622
Q1 2013 $1,604
Q4 2012 $1,586
Q3 2012 $1,568
Q2 2012 $1,546
Q1 2012 $1,555
Q4 2011 $1,558
Q3 2011 $1,585
Q2 2011 $1,705
Q1 2011 $1,745
Q4 2010 $1,733
Q3 2010 $2,080
Q2 2010 $2,157
Q1 2010 $2,187
Q4 2009 $2,204
Q3 2009 $2,192
Q2 2009 $2,154
Q1 2009 $2,088
Q4 2008 $2,141
Q3 2008 $2,897
Q2 2008 $2,891
Q1 2008 $2,845
Q4 2007 $2,806
Q3 2007 $2,736
Q2 2007 $2,664
Q1 2007 $2,568
Q4 2006 $2,558
Q3 2006 $2,503
Q2 2006 $2,617
Q1 2006 $2,410
Q4 2005 $2,538
Q3 2005 $2,589
Q2 2005 $2,548
Q1 2005 $2,627
Sector Industry Market Cap Revenue
Medical Medical Services $6.806B $2.266B
Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Their dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. At Charles River, they are passionate about their role in improving the quality of people's lives. Their mission, their excellent science and strong sense of purpose guide in all that they do, and they approach each day with the knowledge that their work helps to improve the health and well-being of many across the globe. Charles River Laboratories International, Inc. service areas are Basic research, discovery, safety and efficacy, clinical support and manufacturing.
Stock Name Country Market Cap PE Ratio
ICON (ICLR) Ireland $7.857B 24.62
PRA Health Sciences (PRAH) United States $7.388B 30.16
NovoCure (NVCR) Jersey $4.934B 0.00
Premier (PINC) United States $4.928B 16.71
Teladoc (TDOC) United States $4.907B 0.00
HealthEquity (HQY) United States $4.850B 94.81
AMN Healthcare Services Inc (AMN) United States $2.538B 16.46
Medpace Holdings (MEDP) United States $2.504B 30.99
BioTelemetry (BEAT) United States $2.493B 44.03
Intrexon (XON) United States $1.073B 0.00
CareDx (CDNA) United States $1.023B 0.00
Natera (NTRA) United States $1.017B 0.00
Healthways (TVTY) United States $0.871B 9.25
China Cord Blood (CO) China $0.819B 22.47
Apollo Medical Holdings (AMEH) United States $0.682B 0.00
Civitas Solutions (CIVI) United States $0.643B 10.61
Surgery Partners (SGRY) United States $0.637B 0.00
Establishment Labs Holdings (ESTA) $0.527B 0.00
OncoCyte (OCX) United States $0.196B 0.00
Imprimis Pharmaceuticals (HROW) United States $0.147B 0.00
Interpace Diagnostics (IDXG) United States $0.027B 0.00
OpGen (OPGN) United States $0.013B 0.00
Cancer Genetics (CGIX) United States $0.007B 0.00
FORM Holdings (XSPA) United States $0.005B 0.00
Biocept (BIOC) United States $0.002B 0.00